Cystic Fibrosis
Study Outline
The dose-escalating study aims to evaluate the safety, tolerability and efficacy of ARO-ENaC in Cystic Fibrosis patients.
To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.
Eligibility & Requirements
- Aged 18 or over with a diagnosis of cystic fibrosis
- FEV1 between 40% and 90% predicted
- No History of organ transplantation
- Not pregnant or breastfeeding
What's Involved
- You will be required to attend at least 16 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands.
- Complete one phone call for up to approximately 16 weeks (please note, there is also up to 28 days in the screening period of the study).
Principal Investigator
Dr Siobhain Mulrennan
This Clinical Trial is currently Closed
Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.
Current Clinical Trials
Register for a Clinical Trial
Sign up today
Alpha1 Antitrypsin Deficiency
GTi1201
Asthma
AROMUC5AC1001
Asthma
NIMBLE-LITHE
Bronchiectasis
1397-0012
Bronchiectasis
INS1007-301
COPD
D9180C00002
COPD
PACE
Cystic Fibrosis
Bayesian Evidence-Adaptive Treatment in Cystic Fibrosis (BEAT CF)
Cystic Fibrosis
VX20-121-103